Loading...
01/11 11:04
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary and Q&A session indicate positive sentiment. The company announced an additional $1 billion share repurchase, maintaining revenue guidance, and targeting inorganic revenue growth. Despite some delays in longer-cycle projects, there is strong momentum in sectors like wastewater and life sciences. The management's optimism in clean energy and the pharma vertical, coupled with strategic M&A and pricing actions, suggests a positive outlook. However, some uncertainties remain regarding tariffs and guidance clarity. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.
Orders Orders increased by 8% year-over-year with a book-to-bill ratio of 1.03x. Sequentially, orders grew by 3% from Q1 to Q2. The growth was attributed to strong performance in organic order growth and backlog increases.
Aftermarket Revenue Aftermarket revenue accounted for 37% of total revenue, up 100 basis points year-over-year. This increase reflects a strategic focus on aftermarket services.
Adjusted EBITDA Adjusted EBITDA for Q2 was $509 million with a margin of 27%. The year-over-year decline in margin was due to organic volume declines, dilutive impacts from acquisitions, tariff pricing adjustments, and targeted investments for growth.
Adjusted Earnings Per Share (EPS) Adjusted EPS was $0.80 for the quarter, up 18% on a two-year stack. This reflects strong operational performance despite macroeconomic challenges.
Free Cash Flow Free cash flow for Q2 was $210 million, down year-over-year due to the timing of bond interest payments. However, year-to-date free cash flow increased by 13% year-over-year.
Liquidity Total company liquidity stood at $3.9 billion, providing flexibility for value creation opportunities. Leverage improved to 1.7 turns, a 0.3 turn improvement compared to the prior year.
Share Repurchases $500 million was deployed for share repurchases in Q2, representing approximately 6.1 million shares at an average price of $81.35. This reflects a commitment to returning value to shareholders.
ITS Segment Orders ITS segment orders increased by 7% year-over-year and 5% sequentially. Organic order growth was in the low single digits, driven by strong performance in Americas, EMEA, and Asia Pacific regions.
PST Segment Revenue PST segment revenue grew by 17% year-over-year, primarily driven by M&A activities. Adjusted EBITDA for the segment was $117 million, up 14% year-over-year, with a margin of 29.5%.
CompAir Ultima oil-free compressor: Delivers a 14% improvement in energy efficiency with an optimized design, eliminating the need for a gearbox, reducing friction, and increasing reliability and serviceability.
EVO Series electric diaphragm pump: Provides a 15% improvement in energy efficiency, ergonomic single-sided diaphragm for easier maintenance, and supports the ARO Protect care solution to maximize uptime and minimize costs.
Geographical expansion in Asia: Lead Fluid acquisition broadens geographical reach in Asia for the life science platform.
M&A activity: Completed 11 acquisitions in 2025, adding $200 million in annualized revenue at a 9.5x pre-synergy EBITDA multiple. Highlighted acquisitions include Lead Fluid and Termomeccanica Industrial Compressors.
Free cash flow: Generated $210 million in Q2, with year-to-date free cash flow up 13% year-over-year.
Adjusted EBITDA: Achieved $509 million in Q2 with a margin of 27%, despite challenges from organic volume declines and dilutive impacts of recent acquisitions.
Life science platform development: Lead Fluid acquisition introduces advanced peristaltic pump technology and expands presence in Asia. Another bolt-on deal under LOI to further broaden the platform.
Capital allocation strategy: Focused on high-return investments and M&A, with $650 million deployed across 20 acquisitions in the past year, adding $300 million in annualized revenue.
High Pressure Solutions business outlook: The company wrote down the minority stake retained in the High Pressure Solutions business due to changes in the revised long-term outlook driven by the upstream oil and gas market.
ILC Dover impairments: Impairments were recorded due to reduced expectations for Aerospace and Defense business with a certain customer, market-based inputs such as an increase in the discount rate, contraction of peer market multiples, and trade name impairment.
Tariff pricing impact: The company experienced a dilutive impact of tariff pricing matching tariff costs one-for-one, which affected adjusted EBITDA margins.
Organic volume declines: Declines in organic volume led to a year-over-year decrease in adjusted EBITDA margin.
Dynamic macro environment: The company operates in a dynamic macro environment, which poses challenges to maintaining stable operations and financial performance.
M&A risks: Despite a disciplined approach to M&A, impairments related to acquisitions like ILC Dover highlight risks in achieving expected returns and integration challenges.
Full Year 2025 Guidance: The company raised its full-year guidance on revenue, adjusted EBITDA, and adjusted EPS. Adjusted EBITDA midpoint is now $2.13 billion, matching the top end of the previous guidance. Adjusted EPS midpoint is increased to $3.40, up $0.06 or 2% from the previous midpoint.
Revenue Projections: Total revenue guidance is increased, driven by M&A and FX, partially offset by a reduction in tariff-related pricing. Organic revenue change is solely based on reduced tariff pricing assumptions, which do not impact adjusted EBITDA or adjusted EPS.
Capital Expenditures: CapEx is expected to be around 2% of revenue for the full year.
Share Repurchases: The company updated its share count assumption to approximately 403 million shares, reflecting $500 million in share repurchases during Q2. Guidance excludes the effect of any additional share repurchases or M&A later in the year.
Market Conditions and Indicators: Internal indicators show positive signs, with MQLs up double digits in Q2 and continued momentum in July. Large long-cycle funnel activity remains robust, and approved projects are progressing through decision-making processes.
Dividend Payment: $8 million was allocated for dividend payments during the second quarter.
Share Repurchase: $500 million was deployed to share repurchases in the second quarter, representing approximately 6.1 million shares at an average purchase price of $81.35. The company is targeting up to an additional $250 million of share repurchases for the remainder of the year.
The earnings call summary indicates improved guidance, strong order growth, and increased shareholder returns, despite tariff challenges. The Q&A reveals management's confidence in overcoming headwinds and achieving future targets. The positive momentum in organic orders and strategic cost actions further support a positive outlook. The raised guidance and share repurchases are likely to positively influence the stock price.
The earnings call summary and Q&A session indicate positive sentiment. The company announced an additional $1 billion share repurchase, maintaining revenue guidance, and targeting inorganic revenue growth. Despite some delays in longer-cycle projects, there is strong momentum in sectors like wastewater and life sciences. The management's optimism in clean energy and the pharma vertical, coupled with strategic M&A and pricing actions, suggests a positive outlook. However, some uncertainties remain regarding tariffs and guidance clarity. Overall, the sentiment is positive, likely leading to a stock price increase of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
